CE: Updates in Myasthenia Gravis Treatment for Specialty Pharmacists

Pharmacy Times Health Systems Edition, July 2020, Volume 9, Issue 4

Myasthenia gravis is most commonly caused by binding of immunoglobulin G (IgG) antibodies to the postsynaptic acetylcholine receptor (AChR), although other receptors may also be involved.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING LLC.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

• Examine the pathophysiology and disease progression of myasthenia gravis

• Explore the available treatment approaches for myasthenia gravis and myasthenic crisis

• Identify opportunities of intervention for specialty pharmacists to improve patient care and outcomes in management of myasthenia gravis

FACULTY

Michael Erdman, PharmD, BCPS

Critical Care Pharmacist, Neuroscience Intensive Care Unit, UF Health Jacksonville, Jacksonville, Florida

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: June 15, 2020

EXPIRATION DATE: June 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.